189 related articles for article (PubMed ID: 33437015)
1. Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma.
Nurmi AM; Mustonen HK; Stenman UH; Seppänen HE; Haglund CH
Sci Rep; 2021 Jan; 11(1):781. PubMed ID: 33437015
[TBL] [Abstract][Full Text] [Related]
2. Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.
Nurmi AM; Mustonen H; Haglund C; Seppänen H
Oncology; 2021; 99(11):686-698. PubMed ID: 34412062
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
4. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
5. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
6. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
7. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma.
Smith RA; Bosonnet L; Ghaneh P; Raraty M; Sutton R; Campbell F; Neoptolemos JP
Dig Surg; 2008; 25(3):226-32. PubMed ID: 18577869
[TBL] [Abstract][Full Text] [Related]
9. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
10. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
11. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
12. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
Nakamura T; Asano T; Okamura K; Tsuchikawa T; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Shichinohe T; Hirano S
J Gastrointest Surg; 2019 May; 23(5):990-996. PubMed ID: 30242645
[TBL] [Abstract][Full Text] [Related]
13. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer.
Yagyu T; Saito H; Sakamoto T; Uchinaka EI; Morimoto M; Amisaki M; Watanabe J; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2019 Mar; 39(3):1441-1446. PubMed ID: 30842180
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
16. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
17. A new preoperative prognostic scoring system to predict prognosis in patients with locally advanced pancreatic body cancer who undergo distal pancreatectomy with en bloc celiac axis resection: a retrospective cohort study.
Miura T; Hirano S; Nakamura T; Tanaka E; Shichinohe T; Tsuchikawa T; Kato K; Matsumoto J; Kondo S
Surgery; 2014 Mar; 155(3):457-67. PubMed ID: 24462074
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the physiobiological parameter-based grading system for predicting the long-term prognosis after curative surgery for resectable pancreatic cancer.
Abe T; Amano H; Kobayashi T; Hattori M; Hanada K; Nakahara M; Ohdan H; Noriyuki T
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):613-619. PubMed ID: 32978015
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma.
Sumiyoshi T; Uemura K; Shintakuya R; Okada K; Baba K; Harada T; Serikawa M; Ishii Y; Nakamura S; Arihiro K; Murakami Y; Takahashi S
Ann Surg Oncol; 2024 Jul; 31(7):4665-4672. PubMed ID: 38652196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]